Clinical Trials · NCT01960179
Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Sanofi
- Enrollment
- 361
- Start date
- Nov 2013
- Locations
- 30 sites, Japan
- Primary endpoint
- Safety over 24 and 52 weeks assessed by treatment emergent adverse event (TEAE), vital signs, 12-lead electrocardiogram (ECG), and laboratory data.